Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

About this update from Celularity Inc.

[{"type":"list","items":[{"val":[{"type":"text","content":"The contemplated financing transactions would provide up to $12 Million in capital to support Celularity’s strategic priorities around longevity and preservation of human performance.","length":183,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":183,"olType":false},{"type":"text","content":"FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced that it has entered into two binding term sheets for a senior secured term loan and a secured convertible note financing with Philip A. Barach, co-founder and former president of DoubleLine Capital LP, a Los Angeles-based investment management firm. The contemplated financing transactions are contingent upon the parties executing formal transaction agreements, which the parties expect to do shortly.","length":614,"tagName":"p"},{"type":"text","content":"Under the terms of the binding term sheets, Celularity expects to receive initial proceeds of $10.0 million, with the availability of additional funding of up to $2.0 million subject to certain conditions and the investor’s election, as will be set forth in the definitive agreements.","length":284,"tagName":"p"},{"type":"text","content":"“This financing, when completed, is expected to provide flexibility to further evolve our mission, sharpening our focus on advancing our core placental-derived technologies and thoughtfully aligning our organizational structure and resources to support our strategic priorities around longevity and preservation of human performance,” said Robert J. Hariri, M.D., Ph.D., Chairman and Chief Executive Officer of Celularity. “We are grateful to Phil Barach’s commitment to partner with Celularity at an important moment in our progression. Phil’s investment reflects a deep appreciation for the scientific foundation of our platform and the long-term vision we are pursuing.”","length":673,"tagName":"p"},{"type":"text","content":"As contemplated in the binding term sheets, the senior secured term loan has a stated principal amount of $7.0 million and is secured by a first-priority lien on substantially all of Celularity’s assets, subject to certain customary exclusions and priority agreements. The secured convertible ...

More updates from Celularity Inc.